AU2021397319A1 - Combination therapies for the treatment of cancer - Google Patents

Combination therapies for the treatment of cancer Download PDF

Info

Publication number
AU2021397319A1
AU2021397319A1 AU2021397319A AU2021397319A AU2021397319A1 AU 2021397319 A1 AU2021397319 A1 AU 2021397319A1 AU 2021397319 A AU2021397319 A AU 2021397319A AU 2021397319 A AU2021397319 A AU 2021397319A AU 2021397319 A1 AU2021397319 A1 AU 2021397319A1
Authority
AU
Australia
Prior art keywords
compound
formula
cancer
kras
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021397319A
Other languages
English (en)
Other versions
AU2021397319A9 (en
Inventor
Leslie Harris BRAIL
Leenus MARTIN
Robert Field SHOEMAKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasca Inc
Original Assignee
Erasca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasca Inc filed Critical Erasca Inc
Publication of AU2021397319A1 publication Critical patent/AU2021397319A1/en
Publication of AU2021397319A9 publication Critical patent/AU2021397319A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021397319A 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer Abandoned AU2021397319A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124669P 2020-12-11 2020-12-11
US63/124,669 2020-12-11
US202163214736P 2021-06-24 2021-06-24
US63/214,736 2021-06-24
US202163277555P 2021-11-09 2021-11-09
US63/277,555 2021-11-09
US202163283035P 2021-11-24 2021-11-24
US63/283,035 2021-11-24
PCT/US2021/062927 WO2022125971A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2021397319A1 true AU2021397319A1 (en) 2023-07-27
AU2021397319A9 AU2021397319A9 (en) 2024-05-16

Family

ID=81974015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021397319A Abandoned AU2021397319A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Country Status (7)

Country Link
US (1) US20250195533A1 (enExample)
EP (1) EP4259639A4 (enExample)
JP (1) JP2023553534A (enExample)
KR (1) KR20230151981A (enExample)
AU (1) AU2021397319A1 (enExample)
CA (1) CA3201612A1 (enExample)
WO (1) WO2022125971A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
WO2023059771A1 (en) * 2021-10-06 2023-04-13 Erasca, Inc. Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
EP4426303B1 (en) * 2021-11-02 2025-10-08 Semmelweis Egyetem Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers
CN120112284A (zh) 2022-08-19 2025-06-06 米拉蒂治疗股份有限公司 阿达格拉西布固体药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013797B1 (en) * 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
AU2018273356B2 (en) * 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CR20210175A (es) * 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021002804A (es) * 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
US20220152026A1 (en) * 2019-02-12 2022-05-19 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
JP2023553532A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer

Also Published As

Publication number Publication date
KR20230151981A (ko) 2023-11-02
WO2022125971A1 (en) 2022-06-16
EP4259639A1 (en) 2023-10-18
US20250195533A1 (en) 2025-06-19
AU2021397319A9 (en) 2024-05-16
CA3201612A1 (en) 2022-06-16
EP4259639A4 (en) 2024-10-23
JP2023553534A (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
US20250195533A1 (en) Combination therapies for the treatment of cancer
US20170196878A1 (en) Use of cbp/ep300 and bet inhibitors for treatment of cancer
EP2205242B1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20240050441A1 (en) Combination therapies for the treatment of cancer
US20240058352A1 (en) Combination therapies for the treatment of cancer
US11234971B2 (en) Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
TW202409075A (zh) 用莫蘇妥珠單抗及來那度胺治療先前未經治療的濾泡性淋巴瘤之方法
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
CN117120449A (zh) 用于癌症治疗的联合疗法
HK40103172A (zh) 用於癌症治疗的联合疗法
HK40103377A (zh) 用於癌症治疗的联合疗法
HK40103380A (zh) 用於癌症治疗的联合疗法
CN117083283A (zh) 用于癌症治疗的联合疗法
CN117098537A (zh) 用于癌症治疗的联合疗法

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period